There is substantial evidence that cerebrospinal fluid (CSF) levels of both A␤42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both A␤ and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF A␤42 levels were used to stratify the sample into those with and without likely A␤ deposition in the brain the association was only observed in individuals with evidence of A␤ deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain A␤ deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (A␤ deposition) interaction that places changes in CSF tau after A␤ deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.
N eurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein are a feature of many neurodegenerative diseases, collectively known as tauopathies. Alzheimer's disease (AD) is characterized by the presence of NFT and amyloid-beta (A␤) plaques. Association studies between the tau gene (MAPT) and AD have produced inconsistent results (1, 2) . Failure to replicate reported associations is common and frequently due to inadequate power resulting from small sample size and genetic and environmental heterogeneity. Using endophenotypes, the issue of heterogeneity in clinical diagnoses is avoided. Quantitative endophenotypes may provide increased power for genetic studies, because they are measurable in many or all individuals and provide a biological model of disease and the possible effects of the associated genetic variation. Cerebrospinal fluid (CSF) A␤ and tau levels have emerged as promising endophenotypes for AD (3) . Our recent studies show that levels of CSF 42 amino acid A␤ (A␤42) and tau are correlated with AD status, disease severity [as measured by clinical dementia rating (CDR)] and A␤ deposition (4) (5) (6) . CSF tau levels increase in a number of neurodegenerative disorders and are thought to reflect neuronal damage (7) . However, elevated levels of soluble phosphorylated tau appear to be specific to AD (8) . Leveraging the strengths of an endophenotype-based approach, we genotyped 21 SNPs in MAPT in a series of 313 individuals with measured CSF biomarkers.
Results
CSF tau and ptau181 levels approximated a normal distribution after log-log transformation. Tau levels showed 10-fold variation between individuals (mean ϭ 375 pg/ml, range ϭ 88-1358 pg/ml). Ptau181 levels showed similar levels of interindividual variation (mean ϭ 63 pg/ml, range ϭ 24-241 pg/ml). Our analyses showed significant association between CDR and both tau and ptau181 levels (P Ͻ 0.0001 for both tau and ptau181) and association between the apoliprotein E epsilon 4 allele (APOE 4) and ptau181 (P ϭ 0.013) with a similar but not significant (P ϭ 0.090) trend in tau. Age also showed significant association with tau and ptau181 levels, but this effect was not independent of the CDR effect. We observed no significant association between gender and CSF tau or ptau181 levels.
We genotyped 21 SNPs in the MAPT region, including five SNPs that are commonly genotyped in disease association studies and four other SNPs from previous studies (9, 10) [supporting information (SI) Fig. S1 ]. The 21 SNPs that we genotyped tag Ϸ92% of the MAPT SNPs in the HapMap database with an r 2 Ͼ 0.80 (Fig. S2) . Four SNPs showed association with CSF ptau181 levels that survived the false discovery rate (FDR) filter: rs16940758 (intron 2; P ϭ 0.0068), rs3785883 (intron 4; P ϭ 0.0061), rs2435211 (intron 5; P ϭ 0.0057), and rs2471738 (intron 8; P ϭ 0.0098; Table 1 ). The nonparametric Kruskall-Wallis test also yielded significant association for these SNPs. There is strong linkage disequilibrium (LD) between rs2471738 and rs2435211 (DЈ ϭ 1, r 2 ϭ 0.57) and between rs3785883 and rs16940758 (DЈ ϭ 1, r 2 ϭ 0.86) but little LD between the two pairs (r 2 Ͻ 0.15). In each case, the minor allele is associated with increased CSF tau and/or ptau181.
In a subset of the CSF sample, individuals with CSF A␤42 levels less than Ϸ500 pg/ml have been shown to have evidence of A␤ deposition as detected by positron emission tomography, using Pittsburgh compound B (PET PIB), whereas individuals with CSF A␤42 levels greater than Ϸ500 pg/ml have negative PET PIB scans (4, 5) . To evaluate the association in the likely presence or absence of A␤ deposition we used CSF A␤42 levels greater or less than 500 pg/ml to stratify the sample approximating a neuropathological definition of cases and controls. For all four SNPs, we observed significant association in the low A␤42 stratum but not in the high A␤42 stratum ( Table 2) . We also observed significant P values for genotype by A␤42 interaction terms for both tau and ptau181 (tau vs. rs3785883*A␤42, P ϭ 0.0011; ptau181 vs. rs3785883*A␤42 P ϭ 0.0033)
Based on these findings, we genotyped the higher frequency SNP from each high LD pair (rs2435211 and rs3785883) in a sample of 49 Italian AD cases for whom CSF tau and ptau181 had been measured and performed a one-tailed test for association. In the 49 cases, rs2435211 showed significant association with tau (P ϭ 0.013) but not ptau181 (P ϭ 0.11). Rs3785883 showed significant association with both tau (P ϭ 0.0087) and ptau181 (P ϭ 0.023). Consistent with our initial finding, the minor alleles of these SNPs are associated with increased CSF tau and ptau181 levels.
The observation that CSF tau levels are associated with MAPT SNPs only in the presence of A␤ deposition suggests that, rather than affecting risk for AD, these SNPs would influence age at onset (AAO) of clinical symptoms. Specifically, we hypothesized that the minor allele of rs3785883, which is associated with higher CSF tau and ptau181 levels, is associated with earlier AAO of AD. To test this hypothesis, we genotyped rs3785883 in 361 AD cases and 358 age-matched controls and compared the survival curves of the two homozygotes, using a one-tailed Log-rank test. As predicted, the minor allele homozygotes had significantly earlier AAO of AD (P ϭ 0.031; Fig. 1 ) but not risk for AD (1) .
To test the hypothesis that the underlying mechanism involves regulation of gene expression we determined whether the same Minor allele frequency (MAF) and P values for tau and ptau181. Samples were stratified based on CSF A␤42 levels greater or less than Ϸ500 pg/ml as an approximation of amyloid deposition (4, 5) . Values in boldface indicate P values Ͻ0.05.
† Recessive model.
SNPs were also associated with total MAPT mRNA level (Ttau) or the ratio of exon 10ϩ/exon 10Ϫ transcripts (4R/3R). We genotyped rs3785883 in 33 cases and 37 controls in whom Ttau and 4R/3R ratios in the parietal lobe were measured. Because there were only two minor allele homozygotes in the sample, we compared mRNA levels between carriers of the minor allele and noncarriers. In cases, carriers of the minor allele show increased levels of Ttau (P ϭ 0.0095; Fig. 2 ) but no association with 4R/3R ratio. We failed to detect a significant effect in controls for either Ttau or 4R/3R ratio. Association has also been reported between the H1C haplotype of MAPT and risk for late onset Alzheimer disease (LOAD) (2) and progressive supranuclear palsy (11) . Previously, we failed to detect association between the H1C haplotype and risk for LOAD (1) . Here, we also failed to detect association between the H1C haplotype and CSF tau levels ( Table 3 ). The H1U and H1H subhaplotypes showed significant association with CSF tau levels that survived the FDR ϭ 0.1 filter. Using the same set of SNPs, we failed to detect significant association between any haplotypes and AAO or risk for LOAD in our case-control series.
Discussion
Our results suggest that genetic variation in MAPT influences both CSF tau levels and tau mRNA expression. This association appears to be context-dependent; the effect is observed only in individuals with A␤ deposition. This gene by physiological environment interaction was confirmed by performing an analysis, including an interaction term between rs3785883 genotype and CSF A␤42 levels. Our observation strongly supports the hypothesis that A␤ deposition is an early feature of AD pathogenesis that subsequently leads to tangle formation and is consistent with clinicopathological observations (12) and data suggesting that either amyloid precursor protein (APP) or A␤ influences the formation of neurofibrillary tangles (13, 14) .
Association between CSF tau levels (adjusted for duration of disease but not APOE 4 genotype) and rs242557 (P ϭ 0.001) was reported in a series of 89 cases by Laws et al. (15) . In their report, rs3785883 was marginally significant (P ϭ 0.055). In our threefold larger sample, we failed to detect association with rs242557 but found significant association with rs3785883 and several other SNPs in MAPT. Our findings appear to be consistent with those of Laws et al. (15) , suggesting that single SNPs and haplotypes in this region of MAPT are associated with CSF tau levels.
H1 homozygotes have been shown to have increased tau mRNA expression in the cortex (16) . Although our sample size was not sufficient to compare expression levels in H1 and H2 homozygotes, we did perform a haplotypic association test (H1 vs. H2). We observed a P value of 0.27 in the expression controls and a P value of 0.055 in the expression cases. The lack of significance does not exclude the existence of an association as our sample size and thus power for these expression studies is very limited. However, the trend observed in the expression cases is consistent with our single SNP findings, which indicate that the association is stronger in individuals with A␤ deposition. We did not detect association between the H1/H2 haplotypes and CSF tau protein levels (see rs1560310 in Table 1 ). The results of our haplotype analysis (Table  3) show that, of the nine H1 subhaplotypes present in our sample, only two very rare haplotypes showed significant elevation of CSF tau relative to the H2 haplotype. Our data suggest that higher tau mRNA expression associated with H1 may be related to genetic variation within specific H1 subhaplotypes. Haplotypes were estimated from rs1560310, rs1467967, rs242557, rs3785883, rs2471738, and rs7521 (the common allele is represented as Љ1,Љ the rare allele is represented as a Љ2Љ). For each haplotype with a frequency of Ͼ2% in this sample the frequency, additive genetic value and P value for association with CSF tau levels are shown. † Haplotype names from Pittman et al. (27) . Values in boldface indicate P values Ͻ0.05.
Fig. 1.
Survival curves comparing age at onset of LOAD between the common (11) and rare (22) homozygotes of rs3785883.
Although they may not directly affect whether an individual will develop AD or not, polymorphisms in MAPT are associated with the AAO of disease. This pattern of association may be part of the reason our previous study failed to replicate the associations observed by Myers et al. (17) in their neuropathologically diagnosed (ND) samples. The mean age of controls in our series is 4 years younger than the ND series. The inclusion of younger controls may result in an increase in the number of individuals with MAPT risk alleles that have not yet converted to AD thus reducing power to detect the effect. In our CSF series, 24% of the controls have CSF A␤42 levels consistent with PIB retention in the brain indicative of A␤ deposition, which, in addition to limited sample sizes and genetic and environmental heterogeneity, may help explain the inconsistent evidence for MAPT single SNP and haplotype associations in LOAD case-control studies.
In conclusion, our data indicate that A␤ deposition directly or indirectly leads to an induction of MAPT gene expression, leading to increased CSF tau levels and increased neurodegeneration as evidenced by earlier AAO of LOAD. These findings also highlight the utility and potential of this endophenotype-based approach for understanding both the genetic etiology and pathobiology of LOAD.
Materials and Methods
Subjects. Our initial CSF sample consists of 313 European American volunteers participating in studies of aging and dementia at the Alzheimer Disease Research Center at the Washington University School of Medicine from July of 1998 to October of 2006 (18) . Approximately 63% of our sample is female, 43-95 years of age (Table 4) . Approximately 72% of the sample has a clinical dementia rating (CDR) of 0 (nondemented), whereas 20% of individuals have a CDR of 0.5 (very mild dementia) and 8% of individuals have a CDR of 1.0 (mild dementia) (19) . Just more than 42% of the individuals in this sample carry at least one apolipoprotein E epsilon 4 (APOE 4) allele.
The replication CSF sample is an Italian sample consisting of 49 AD cases from whom CSF has been collected. Dementia severity was assessed by using the CDR and the Mini Mental State Examination. The diagnosis of probable AD was made by exclusion according to National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria. Informed consent to participate in this study was given by all individuals or their caregivers.
The case-control series used in this study was collected through the ADRC patient registry. Cases in this series received a diagnosis of dementia of the Alzheimer's type (DAT), using criteria equivalent to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association, modified slightly to include AD as a diagnosis for individuals aged Ͼ90 years (20, 21) . A total of 361 unrelated DAT cases with a minimum age at onset (AAO) of 60 years were recruited for the study. DNA from 358 age-and sex-matched nondemented controls aged Ͼ60 years at assessment were obtained through the ADRC.
Endophenotypes. CSF was collected from all individuals in the Washington University School of Medicine CSF series. CSF collection, processing, and biomarker measurements were performed as described by Fagan et al. (4) . To minimize variability, all draws occurred at 8 a.m. after 12 h of fasting (22) . All studies were approved by the Washington University School of Medicine Human Studies Committee, and informed consent was obtained from all subjects.
Italian CSF samples were also obtained after fasting. Samples were collected in polypropylene tubes by LP at the L4/L5 or L3/L4 interspace, centrifuged at 4°C and stored at or below Ϫ30°C until analysis. A␤42, tau, and ptau181 CSF levels were determined with human-specific ELISA kits (Innogenetics) as reported in ref. 23 .
sets of SNPs that have been used for previous haplotype analyses in MAPT for association with CSF tau levels, AAO, and risk for LOAD (27) .
